Abstract
Development of novel therapeutic strategies is a continuing challenge for the treatment of acute myeloid leukemia (AML). The novel triterpenoid, C-28 methyl ester of 2-cyano-3,12-dioxoolen-1,9-dien-28-oic acid (CDDO-Me), induces apoptosis in myeloid leukemic cell lines and in primary AML samples. In this report, the effects of CDDO-Me on CD34+ AML progenitor cells in vitro were examined. CDDO-Me induced apoptosis in all but one of ten AML samples. CDDO-Me is known to inhibit the activation of ERK1/2. In this series of primary AML samples, ERK was expressed and phosphorylated in all patient samples studied and CDDO-Me inhibited ERK phosphorylation in five of 10 samples. However, CDDO-Me induced apoptosis in four of five samples without decreasing pERK levels, suggesting that pERK is not the sole target of the compound. CDDO-Me induced phosphorylation of p38 in AML-derived U937 cells. Pretreatment of U937 cells with a p38 inhibitor protected cells from the cyto-toxic effects of CDDO-Me. These findings suggest a role for p38 in CDDO-Me-induced apoptosis. In preliminary studies, CDDO-Me induced p38 phosphorylation in seven of eight primary AML samples. These findings suggest that CDDO-Me treatment shifts cell signaling away from cyto-protective pathways and thus CDDO-Me may be effective for the treatment of AML.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Cobb MH, Goldsmith EJ . How MAP kinases are regulated. J Biol Chem 1995; 270: 14843–14846.
Kyriakis JM, Avruch J . Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 2001; 81: 807–869.
Chen Z, Gibson TB, Robinson F, Silvestro L, Pearson G, Xu B et al. MAP kinases. Chem Rev 2001; 101: 2449–2476.
Chang F, Steelman LS, Lee JT, Shelton JG, Navolanic PM, Blalock WL et al. Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia 2003; 17: 1263–1293.
Chen RH, Juo PC, Curran T, Blenis J . Phosphorylation of c-Fos at the C-terminus enhances its transforming activity. Oncogene 1996; 12: 1493–1502.
Deng X, Ruvolo P, Carr B, May WS . Survival function of ERK1/2 as IL-3-activated, staurosporine-resistant Bcl2 kinases. Proc Natl Acad Sci USA 2000; 97: 1578–1583.
Hoffmann R, Baillie GS, MacKenzie SJ, Yarwood SJ, Houslay MD . The MAP kinase ERK2 inhibits the cyclic AMP-specific phosphodiesterase HSPDE4D3 by phosphorylating it at Ser579. EMBO J 1999; 18: 893–903.
Ku H, Meier KE . Phosphorylation of paxillin via the ERK mitogen-activated protein kinase cascade in EL4 thymoma cells. J Biol Chem 2000; 275: 11333–11340.
Towatari M, Iida H, Tanimoto M, Iwata H, Hamaguchi M, Saito H . Constitutive activation of mitogen-activated protein kinase pathway in acute leukemia cells. Leukemia 1997; 11: 479–484.
Blalock WL, Weinstein-Oppenheimer C, Chang F, Hoyle PE, Wang XY, Algate PA et al. Signal transduction, cell cycle regulatory, and anti-apoptotic pathways regulated by IL-3 in hematopoietic cells: possible sites for intervention with anti-neoplastic drugs. Leukemia 1999; 13: 1109–1166.
Fan M, Chambers TC . Role of mitogen-activated protein kinases in the response of tumor cells to chemotherapy. Drug Resist Update 2001; 4: 253–267.
Milella M, Kornblau SM, Estrov Z, Carter BZ, Lapillonne H, Harris D et al. Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest 2001; 108: 851–859.
Milella M, Estrov Z, Kornblau SM, Carter BZ, Konopleva M, Tari A et al. Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia. Blood 2002; 99: 3461–3464.
Andreeff M, Milella M, Carter BZ, Tabe Y, Ricciardi MR, Sneed T et al. Targeted therapy of AML new concepts. Ann Hematol 2004; 83 (Suppl. 1): S51–S53.
Ruvolo PP, Deng X, Ito T, Carr BK, May WS . Ceramide induces Bcl2 dephosphorylation via a mechanism involving mitochondrial PP2A. J Biol Chem 1999; 274: 20296–20300.
Konopleva M, Tsao T, Ruvolo P, Stiouf I, Estrov Z, Leysath CE et al. Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia. Blood 2002; 99: 326–335.
Ito Y, Pandey P, Place A, Sporn MB, Gribble GW, Honda T et al. The novel triterpenoid 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid induces apoptosis of human myeloid leukemia cells by a caspase-8-dependent mechanism. Cell Growth Differ 2000; 11: 261–267.
Stadheim TA, Suh N, Ganju N, Sporn MB, Eastman A . The novel triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO) potently enhances apoptosis induced by tumor necrosis factor in human leukemia cells. J Biol Chem 2002; 277: 16448–16455.
Lapillonne H, Konopleva M, Tsao T, Gold D, McQueen T, Sutherland RL et al. Activation of peroxisome proliferator-activated receptor gamma by a novel synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest and apoptosis in breast cancer cells. Cancer Res 2003; 63: 5926–5939.
Suh WS, Kim YS, Schimmer AD, Kitada S, Minden M, Andreeff M et al. Synthetic triterpenoids activate a pathway for apoptosis in AML cells involving downregulation of FLIP and sensitization to TRAIL. Leukemia 2003; 17: 2122–2129.
Ikeda T, Nakata Y, Kimura F, Sato K, Anderson K, Motoyoshi K et al. Induction of redox imbalance and apoptosis in multiple myeloma cells by the novel triterpenoid 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid. Mol Cancer Ther 2004; 3: 39–45.
Jarvis WD, Fornari Jr FA, Auer KL, Freemerman AJ, Szabo E, Birrer MJ et al. Coordinate regulation of stress- and mitogen-activated protein kinases in the apoptotic actions of ceramide and sphingosine. Mol Pharmacol 1997; 52: 935–947.
Clodi K, Kliche K-O, Zhao S, Weidner D, Schenk T, Consoli U et al. Cell-surface exposure of phosphatidylserine correlates with the stage of fludarabine-induced apoptosis in chronic lymphocytic leukemia (CLL) and expression of apoptosis-regulating genes. Cytometry 2000; 40: 19–25.
Ruvolo PP . Intracellular signal transduction pathways activated by ceramide and its metabolites. Pharmacol Res 2003; 47: 383–392.
Waskiewicz AJ, Flynn A, Proud CG, Cooper JA . Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2. EMBO J 1997; 16: 1909–1920.
Raman M, Cobb MH . MAP kinase modules: many roads home. Curr Biol 2003; 13: R886–R888.
Acknowledgements
This research was supported by Leukemia and Lymphoma Society (MK) and the National Institutes of Health RO1 CA089346 (MA).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Konopleva, M., Contractor, R., Kurinna, S. et al. The novel triterpenoid CDDO-Me suppresses MAPK pathways and promotes p38 activation in acute myeloid leukemia cells. Leukemia 19, 1350–1354 (2005). https://doi.org/10.1038/sj.leu.2403828
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2403828
Keywords
This article is cited by
-
Synthetic triterpenoids have cytotoxicity in pediatric acute lymphoblastic leukemia cell lines but cytotoxicity is independent of induced ceramide increase in MOLT-4 cells
Leukemia (2008)
-
Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer
Nature Reviews Cancer (2007)
-
Synthetic triterpenoids inhibit growth and induce apoptosis in human glioblastoma and neuroblastoma cells through inhibition of prosurvival Akt, NF-κB and Notch1 signaling
Journal of Neuro-Oncology (2007)